![](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/08\/rdy0934_ex99-1img01.jpg\")
<\/p>\n\u00a0<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
\u00a0<\/p>\n
Washington, D.C. 20549<\/p>\n
\u00a0<\/p>\n
Form 6-K<\/p>\n
\u00a0<\/p>\n
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16<\/p>\n
UNDER THE SECURITIES EXCHANGE ACT OF 1934<\/p>\n
\u00a0<\/p>\n
August, 2026<\/p>\n
\u00a0<\/p>\n
Commission File Number 1-15182<\/p>\n
\u00a0<\/p>\n
DR. REDDY\u2019S LABORATORIES LIMITED<\/p>\n
(Translation of registrant\u2019s name into English)<\/p>\n
\u00a0<\/p>\n
8-2-337, Road No. 3, Banjara Hills<\/p>\n
Hyderabad, Telangana 500 034, India<\/p>\n
+91-40-49002900<\/p>\n
\u00a0<\/p>\n
(Address of principal executive office)<\/p>\n
\u00a0<\/p>\n
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<\/p>\n
\u00a0<\/p>\n
Form 20-F\u00a0\u00a0x\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Form 40-F\u00a0\u00a0\u00a8<\/p>\n
\u00a0<\/p>\n
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):\u00a0 ______<\/p>\n
\u00a0<\/p>\n
Note:\u00a0 Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.<\/p>\n
\u00a0<\/p>\n
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):\u00a0 ______<\/p>\n
\u00a0<\/p>\n
Note:\u00a0 Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant\u2019s \u201chome country\u201d), or under the rules of the home country exchange on which the registrant\u2019s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant\u2019s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.<\/p>\n
\u00a0<\/p>\n
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.<\/p>\n
\u00a0<\/p>\n
Yes\u00a0\u00a0\u00a8\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0No\u00a0\u00a0x<\/p>\n
\u00a0<\/p>\n
If \u201cYes\u201d is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
EXHIBITS <\/p>\n
\u00a0<\/p>\n
Exhibit<\/p>\n
Number<\/p>\n
\u00a0<\/p>\n
Description of Exhibits<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
99.1<\/p>\n
<\/p>\n
Intimation dated August 7, 2026 <\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
SIGNATURES <\/p>\n
\u00a0<\/p>\n
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. <\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
DR. REDDY\u2019S LABORATORIES LIMITED <\/p>\n
(Registrant)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Date: August 7, 2026 \u00a0<\/p>\n
By:<\/p>\n
\/s\/ K Randhir Singh<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Name:<\/p>\n
K Randhir Singh<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Title:<\/p>\n
Company Secretary<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Exhibit 99.1<\/p>\n
\u00a0<\/p>\n
<\/p>\n
Dr. Reddy’s Laboratories Ltd.<\/p>\n
8-2-337, Road No. 3, Banjara Hills<\/p>\n
Hyderabad \u2013 500 034, Telangana, India <\/p>\n
\u00a0<\/p>\n
CIN: L85195TG1984PLC004507<\/p>\n
\u00a0<\/p>\n
Tel:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 + 91 40 4900 2900<\/p>\n
Fax:\u00a0\u00a0\u00a0\u00a0 + 91 40 4900 2999<\/p>\n
Email: mail@drreddys.com<\/p>\n
Web:\u00a0\u00a0 www.drreddys.com<\/p>\n
\u00a0<\/p>\n
August 7, 2026<\/p>\n
\u00a0<\/p>\n
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)<\/p>\n
BSE Limited (Scrip Code: 500124)<\/p>\n
New York Stock Exchange Inc. (Stock Code: RDY)<\/p>\n
NSE IFSC Ltd. (Stock Code: DRREDDY)<\/p>\n
\u00a0<\/p>\n
Dear Sir\/Madam,<\/p>\n
\u00a0<\/p>\n
Ref: <\/p>\n
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<\/p>\n
\u00a0<\/p>\n
This is to inform you that the Company has terminated the agreement dated February 11, 2022, with Novartis India Limited (NIL) with respect to the distribution and promotion of select brands in India. This termination follows a change in the controlling shareholding of NIL. The Company will continue to commercialize the brands covered thereunder until September 30, 2026.<\/p>\n
\u00a0<\/p>\n
This is for your information and records.<\/p>\n
\u00a0<\/p>\n
Thanking you,<\/p>\n
\u00a0<\/p>\n
Yours faithfully,<\/p>\n
For Dr. Reddy\u2019s Laboratories Limited<\/p>\n
![](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/08\/rdy0934_ex99-1img02.jpg\")
<\/p>\n
K Randhir Singh<\/p>\n
Company Secretary, Compliance Officer & Head-CSR<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 SECURITIES AND EXCHANGE COMMISSION \u00a0 Washington, D.C. 20549 \u00a0 Form 6-K \u00a0 REPORT OF FOREIGN PRIVATE ISSUER…\n","protected":false},"author":2,"featured_media":113764,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[55399,55400,9463,33970,55401,206,9922,55398,55402],"class_list":["post-113763","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-brand-promotion","tag-controlling-shareholding-change","tag-distribution-agreement","tag-dr-reddys","tag-india-pharmaceuticals","tag-novartis","tag-novartis-india","tag-rdy","tag-sec-form-6-k"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117072487294289373","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/113763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=113763"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/113763\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/113764"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=113763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=113763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=113763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}